Pluto Bioinformatics

GSE64550: shRNA knockdown of YAP1 in HCC364 cells, various drug conditions

Bulk RNA sequencing

Through a genetic screen in BRAF mutant tumor cells, we show that the Hippo pathway effector YAP acts as a parallel survival input to promote resistance to RAF-MEK inhibitor therapy. Our data uncover YAP as a novel mechanism of resistance to RAF-MEK targeted therapy. The findings unveil the synthetic lethality of YAP and RAF-MEK co-suppression as a promising strategy to enhance response and patient survival. SOURCE: Saurabh Asthana (saurabh.asthana@ucsf.edu) - Bivona UCSF